Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|December 5, 2015
Prevalence of Cognitive Impairment Among Peritoneal Dialysis Patients, Impact on Peritonitis and Role of Assisted DialysisYat Fung Shea, Man Fai Lam, Mi Suen Connie Lee, et al.
Blood|September 30, 2018
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseCraig H Moskowitz, Jan Walewski, Auayporn Nademanee, et al.
Cold Spring Harbor Molecular Case Studies|August 10, 2019
Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphomaHammad Tashkandi, Kseniya Petrova-Drus, Connie Lee Batlevi, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 15, 2014
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutationsRobert Shenkar, Changbin Shi, Tania Rebeiz, et al.
Blood Advances|March 14, 2025
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX studyBei Hu, Patrick M Reagan, Laurie H Sehn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2026
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO TrialMatthew Matasar, Zhiming Li, Theodoros P Vassilakopoulos, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Cancers|March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical SettingSerena Zheng, Kanika Gupta, Piyush Goyal, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Pageof 6